HPN and cancer: In a mammary gland model, hepsin was found to downregulate its inhibitor hepatocyte growth factor (HGF) activator inhibitor type 1 (HAI-1), leading to enhanced proteolytic activity, activation of cancer-relevant targets, and disruption of desmosomal and hemidesmosomal structures, finally resulting in a loss of epithelial cohesion7.